Resverlogix Corporation is Featured as the Daily Momentum Gainer to Watch on

Toronto, Ontario--(Newsfile Corp. - July 5, 2013) - Leading smallcap investor portal Smallcappower is pleased to highlight Resverlogix Corporation (TSX: RVX) as their Daily Momentum Gainer to watch. You can see the chart and view the analyst's summary here:

During yesterday's trading session (Thursday), RVX was top gainer in the Canadian health-care sector having gained over 25% and closed at C$0.84 recording significant trading volumes of 2.01 million shares. RVX continued the momentum during its third trading session yesterday after touching its 52-week low last week when it revealed that its Phase 2b ASSURE clinical trial evaluating RVX-208 in high-risk cardiovascular patients with low high-density lipoprotein (HDL) did not meet its primary endpoint of a -0.6% change in percent atheroma volume as determined by intravascular ultrasound (IVUS). RVX was among the most actively traded stocks during yesterday's trade.

About (SCP) is the industry's most trusted resource for small cap stocks, offering unprecedented access to the research and tools you need to help uncover the next big thing. Through a unique Post Media branding association, this online platform gets coast-to-coast media exposure in nine daily newspapers as well as the and websites. is also the exclusive online destination to access Ubika Research reports, CEO video interviews and analysis.

Disclosure: Except for the historical information presented herein, matters discussed in this document contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.

Ubika Research and (are both divisions of Ubika Corporation), and are not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this report. For making specific investment decisions, readers should seek their own advice. For full disclosure please visit:

For additional information contact: